CLEARANCE OF AMYLOID-BETA IN
ALZHEIMER’S DISEASE

To understand the pathogenesis and develop potential therapies in animal models

A THESIS SUBMITTED IN TOTAL FULFILMENT OF THE REQUIREMENTS OF THE DEGREE OF DOCTOR OF PHILOSOPHY

BY

Yan-Jiang Wang
Doctor of Medicine (Neurology)
Master of Medicine (Preventive Medicine)
Bachelor of Medicine (Clinical Medicine)

Department of Human Physiology, Centre for Neuroscience, School of Medicine, Flinders University, Adelaide, South Australia

November 2009
# TABLE OF CONTENTS

THESIS SUMMARY .......................................................................................................................... VI

DECLARATION ................................................................................................................................... VIII

SCHOLARSHIPS SUPPORTING THE PHD STUDY ................................................................. IX

PERSONAL PUBLICATIONS AND CONFERENCE PRESENTATIONS ...... X

ACKNOWLEDGEMENTS .................................................................................................................. XII

CHAPTER 1 ........................................................................................................................................ 1

Literature review: Clearance of Amyloid-beta in Alzheimer's Disease

INTRODUCTION ................................................................................................................................. 2

RECEPTOR-MEDIATED Aβ TRANSPORT ACROSS BLOOD-BRAIN BARRIER (BBB) ...... 4

- Efflux of Aβ from CNS to plasma .......................................................................................... 4
- LRP-mediated Aβ efflux .......................................................................................................... 4
- P-glycoprotein mediated Aβ efflux ......................................................................................... 6

- Influx of Aβ from plasma to CNS .......................................................................................... 6
- RAGE-mediated Aβ influx ....................................................................................................... 7
- gp330/megalin-mediated Aβ influx ........................................................................................ 8

ENZYME-MEDIATED Aβ DEGRADATION ............................................................................. 10

- Neprilysin ............................................................................................................................... 10
- Insulin degrading enzyme (IDE) ............................................................................................ 11
- Other enzymes associated with Aβ degradation ................................................................. 12

NATURAL ANTI-Aβ AUTOANTIBODIES ............................................................................. 14

THERAPEUTIC CLEARANCE OF Aβ ..................................................................................... 15

- Immunotherapy-mediated Aβ clearance ............................................................................... 15
- Active immunotherapy ........................................................................................................... 15
- Passive immunotherapy .......................................................................................................... 16
- Mechanisms of Aβ clearance by immunotherapy ................................................................. 17
- Adverse effect of immunotherapy .......................................................................................... 18
- Improvement of vaccine .......................................................................................................... 20
- Modification of anti-Aβ antibody .......................................................................................... 22
- Anti-Aβ single chain antibody (scFv) .................................................................................... 22
Targeting Aβ oligomers ................................................................. 23
Aβ binding substance-mediated Aβ clearance ......................... 25
CONCLUSIONS .................................................................................. 26
CHAPTER 2 .......................................................................................... 27
Intramuscular Delivery of a Single Chain Antibody Gene Prevents Brain Aβ
Deposition and Cognitive Impairment in a Mouse Model of Alzheimer’s Disease
SUMMARY .......................................................................................... 28
INTRODUCTION .................................................................................. 29
MATERIALS AND METHODS ............................................................. 30
  Animals .......................................................................................... 30
  rAAV vector construction and production ................................ 30
  Muscle injection ........................................................................... 31
  Behavioral test ............................................................................ 31
  Tissue sampling .......................................................................... 32
  Expression of transgenes .......................................................... 33
  Histology and image quantification ......................................... 33
  Quantification of Aβ peptide levels in the brain and plasma by ELISA .... 35
  Quantification of inflammatory cytokines in the brain and plasma by ELISA.. 35
  ELISA assay for antibodies against scFv in mice after intramuscular delivery of
  rAAV-scFv. .................................................................................. 36
  Statistical analysis ...................................................................... 36
RESULTS ................................................................................................ 36
  Expression of scFv gene after intracranial and intramuscular delivery .... 36
  These histological and biochemical data indicate that intramuscular delivery of
  scFv gene effectively prevents Aβ accumulation and deposition in the brain... 40
  Intramuscular delivery of scFv gene attenuates AD-type pathologies ........ 40
  Intramuscular delivery of scFv gene prevents amyloid-associated cognitive
  impairments ............................................................................... 41
  Intramuscular delivery of scFv gene is well tolerated and does not cause
  inflammation and microhemorrhage in the injection sites and brain .......... 41
  ScFv has low immunogenicity and does not induce antibodies ............... 42
DISCUSSION ....................................................................................... 43
CONCLUSIONS .................................................................................. 46
CHAPTER 3 ................................................................................................................................. 48

Grape Seed Derived Polyphenols Attenuate Amyloid-beta Neuropathology in the Brain of Alzheimer’s Disease Mice

SUMMARY .................................................................................................................................. 49

INTRODUCTION .......................................................................................................................... 50

MATERIAL AND METHODS ........................................................................................................ 51

  Transgenic mouse model ........................................................................................................ 51
  HPLC analysis of polyphenols in GSE .................................................................................. 52
  Diets ........................................................................................................................................ 52
  Tissue sampling ...................................................................................................................... 53
  AD-type pathology and quantitative image analysis .............................................................. 54
  Quantification of Aβ peptide levels in the mouse brain and plasma by ELISA .................. 55
  Western blot for APP and BACE expression ....................................................................... 55
  Quantification of TNFα, IL-1β and IFN-γ in the mouse plasma by ELISA ......................... 56
  Assessment of toxicity of polyphenol from grape seeds ..................................................... 56
  Statistical analysis ................................................................................................................ 56

RESULTS ..................................................................................................................................... 57

  Chemical analysis of polyphenols in GSE ............................................................................ 57
  GSE is well tolerated in APPSwe/PS1dE9 transgenic mice ................................................ 57
  GSE reduces brain and serum Aβ levels and prevents Aβ deposition in APPSwe/PS1dE9 transgenic mice ........................................................................................................... 58
  GSE does not change the expression of APP and BACE1 in the brain of APPSwe/PS1dE9 transgenic mice ........................................................................................................... 60
  GSE prevents AD-type neuropathology in APPSwe/PS1dE9 transgenic mice ................. 60
  Plasma and brain levels of inflammatory cytokines after GSE consumption .................... 61

DISCUSSIONS ............................................................................................................................ 62

CONCLUSIONS .......................................................................................................................... 66

CHAPTER 4 .................................................................................................................................. 68

Deletion of P75NTR Reduces Aβ Production But Exacerbates Aβ Pathology by Increasing Aβ Deposition in an Alzheimer’s Disease Mouse Model

SUMMARY .................................................................................................................................. 69

INTRODUCTION .......................................................................................................................... 70
MATERIALS AND METHODS ............................................................... 72
Generation of APPSwe/PS1dE9 transgenic mice with deletion of p75NTR gene ................................................................. 72
Behavioural test .................................................................................. 73
Tissue sampling ....................................................................................... 74
AD-type pathology and quantitative image analysis ....................... 74
Quantification of Aβ peptide levels by ELISA ................................. 76
APP proteolytic processing and α, β, γ-secretase activities ............. 77
Western blot analysis ............................................................................. 78
Primary cortical neuron culture .......................................................... 79
Effects of p75NTR extracellular domain on Aβ oligomerization and fibrillation ............................................................ 79
Hippocampus injection of p75/Fc and Aβ plaque analysis .......... 81
Statistical analysis ................................................................................. 81
RESULTS ............................................................................................... 82
Expression pattern of p75NTR in the brain of APPSwe/PS1dE9 transgenic mice ............................................................. 82
Deletion of p75NTR exacerbates Aβ-related pathologies ............. 83
Deletion of p75NTR increases insoluble Aβ but decreases soluble Aβ levels in the brain ..................................................... 84
Deletion of p75NTR does not affect APP proteolytic processing .... 86
Deletion of p75NTR decreases Aβ production in vitro ..................... 87
Deletion of p75NTR does not affect Aβ degrading enzymes in the brain .......... 87
Recombinant extracellular domain of p75NTR inhibits the formation of Aβ fibrils ................................................................. 88
Deletion of p75NTR exacerbates other AD type pathologies .......... 89
Deletion of p75NTR does not lessen memory deficits till nine months of age .................................................. 90
DISCUSSION ....................................................................................... 90
CONCLUSIONS .................................................................................. 95
CHAPTER 5 ......................................................................................... 96
Future Directions
1. INTRAMUSCULAR DELIVERY OF A SINGLE CHAIN ANTIBODY GENE PREVENTS BRAIN Aβ DEPOSITION AND COGNITIVE IMPAIRMENT IN A MOUSE MODEL OF AD .. 97
(1) What is the mechanism underlying the Aβ reducing effect of the scFv? ..... 98
(2) How to improve the therapeutic effect of the scFv? ..................................... 98
(3) Whether the scFv is able to inhibit Aβ oligomerization and block the neurotoxicity of Aβ. ........................................................................................................... 99

2. GRAPE SEED DERIVED POLYPHENOLS ATTENUATE AMYLOID-BETA NEUROPATHOLOGY IN THE BRAIN OF AD MICE ...................................................... 100
(1) What are the mechanisms of the Aβ reducing effect of grape seed derived polyphenols? ........................................................................................................ 100
(2) Which components of GSE are active in reducing Aβ in the brain?......... 101
(3) Are grape seed derived polyphenols also able to treat other protein misfolding diseases? .............................................................................................. 101

3. DELETION OF P75NTR REDUCES Aβ PRODUCTION BUT EXACERBATES Aβ PATHOLOGY BY INCREASING Aβ DEPOSITION IN AN AD MOUSE MODEL .............. 102
(1) What is the mechanism for promotion of Aβ production by p75NTR? ..... 102
(2) What are the roles of p75NTR in the neuronal degeneration in AD? ...... 103
(3) Development of novel therapies targeting p75NTR ................................. 104

SUMMARY ................................................................................................................. 104

BIBLIOGRAPHY ..................................................................................................... 106
Alzheimer’s disease (AD) is the most common cause of dementia. No strong disease-modifying treatments are currently available. Amyloid-beta peptide (Aβ) appears to play a pivotal role in the pathogenesis of AD. We focused our interest on revealing the pathogenesis of the disease and developing novel therapeutic modalities. The thesis consists of three projects:

1. Prevention of AD by intramuscular delivery of an anti-Aβ single chain antibody (scFv) gene

Immunotherapy is effective in removing brain Aβ, but was associated with detrimental effects. In the present study, the gene of an anti-Aβ scFv was delivered in the hind leg muscles of APPSwe/PS1dE9 mice with adeno-associated virus at three months of age. Six months later, we found that brain Aβ accumulation, AD-type pathologies and cognitive impairment were significantly attenuated in scFv-treated mice relative to enhanced green fluorescence protein (EGFP)-treated mice. Intramuscular delivery of scFv gene was well tolerated by the animals. These findings suggest that peripheral application of scFv is effective and safe in preventing the development of AD, and would be a promising non-inflammatory immunological modality for prevention and treatment of AD.

2. Prevention of AD with grape seed derived polyphenols

Polyphenols extracted from grape seeds are able to inhibit Aβ aggregation, reduce Aβ production and protect against Aβ neurotoxicity in vitro. We investigated the therapeutic effects of a polyphenol-rich grape seed extract (GSE) in vivo.
APPSwe/PS1dE9 transgenic mice were fed with normal AIN-93G diet (control diet), AIN-93G diet with 0.07% curcumin, or diet with 2% GSE beginning at 3 months of age for 9 months. Total phenolic content of GSE was 592.5 mg/g dry weight, including gallic acid, catechin, epicatechin and proanthocyanidins. Long-term feeding of GSE diet was well tolerated. The Aβ levels in the brain and serum of the mice fed with GSE were reduced by 33% and 44% respectively compared with the mice fed with the control diet. Amyloid plaques and microgliosis in the brain of mice fed with GSE were also reduced by 49% and 70% respectively. In conclusion, polyphenol-rich GSE is promising to be a safe and effective drug to prevent the development of AD.

3. Roles of p75NTR in the development of AD

P75NTR has been suggested to mediate Aβ induced neurotoxicity. However, its role in the development of AD is undetermined. APPSwe/PS1dE9 transgenic mice were crossed with p75NTR knockout mice to generate APPSwe/PS1dE9 mice with p75NTR gene deleted. P75NTR mainly expressed in the basal forebrain neurons and degenerative neurites in neocortex and hippocampus. Genetic deletion of p75NTR gene in APPSwe/PS1dE9 mice reduced soluble Aβ levels, but increased the insoluble Aβ accumulation and Aβ plaque formation in the brain. P75NTR deletion decreased Aβ production of cortical neurons in vitro. Recombinant extracellular domain of p75NTR attenuated the oligomerization and fibrillation of synthetic Aβ42 peptide in vitro, and reduced local Aβ plaques after hippocampus injection in vivo. Our data suggest that p75NTR plays an important role in AD development and may be a valid therapeutic target for the treatment of AD.
DECLARATION

I certify that this thesis does not incorporate without acknowledgment any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

The author acknowledges that copyright of published work contained within this thesis resides with the copyright holder/s of those works.

Yan-Jiang Wang

November 2009
SCHOLARSHIPS SUPPORTING THE PHD STUDY


2. Overseas Conference Travel Grant. Flinders University, 2008

PERSONAL PUBLICATIONS AND CONFERENCE PRESENTATIONS

Refereed journal articles


Conference proceedings


ACKNOWLEDGEMENTS

This PhD study has led me on a fantastic journey to explore the science and enjoy its nature. It has been filled with challenges, setbacks, frustrations, successes and excitement. Throughout all these endeavours, there has been encouragement and support.

Firstly, I would like to thank my supervisor, Professor Xin-Fu Zhou, for his experience and wealth of knowledge which have provided me with an immeasurable source of support and advice throughout my PhD years. His supervision has helped me build up my career and provided me with solid foundations for my future pathways. He has dedicated most of his time to scientific research; his passion for science has motivated me and encouraged me to devote my career in science.

Secondly, many thanks to my co-supervisors, Professor Michael Fenech at CSIRO and A/Professor Dominic Thyagarajan at Department of Neurology of FMC, for providing excellent critical review of my thesis. In particular, thanks go to Dominic for providing me with the opportunity to learn from the weekly Neurology Grand Round and Neuroradiology sessions, for inviting my wife to observe the clinical drug trials in his department, which also led to the re-union of my family in Australia.

The work contained in this thesis could not be fully accomplished without the support and expertise of Neuroregeneration laboratory members, Jenny Zhong, Xiao-Hong Liu, Anthony Pollard, Deborah Valadares, Changyue Gao, Yin Sun, Ira Wong, Miao Yang, Yoon Lim, Ernesto Aguilar, Jing-Xian Mi, Hong-Yun Li and Linda Wu. Special thanks to Miss Jenny Zhong for her support and encouragement throughout my PhD study. Many thanks to Miss Xiao-Hong Liu, for her intensive technical
assistance in behavioural test, tissue sampling, section cutting, and Western blotting in scFv and p75NTR projects.

I would also like to thank the Department of Human Physiology, Professor Simon Brookes, Karen Price, Tim Chataway, Jennifer Clarke, and other colleagues in the department for the kind support throughout the time I spent here.

I would also like to give thanks to the Animal House staff, Ray Yates, Theresa, Stuart, Eloise, Jada, and Brooke, for their long term support with the animal maintenance and breeding utilised in my study.

Many thanks to Dr. Qiao-Xin Li, and other members of the Collin Masters group in the Department of Pathology, University of Melbourne, for their expertise and contribution in the Western blot analysis of APP proteolytic processing (Figure 4.4) and ELISA measurement of Aβ in cortical neurons (Figure 4.6) in p75NTR project; thanks to Dr. Phillip Thomas and Dr. Shantha Kosaraju in CSIRO for the collaboration in the grape seed extract project, and for HPLC analysis of phenolic compounds in GSE (Figure 3.1); thanks to Dr. Xiao-Bin Wu in Chinese Center for Disease Control and Prevention for preparing the AAV vectors for the scFv project.

I would also like to thank my landlord Miss Sue, Mr. Lyall and Eddy for looking after me, being like a second family throughout my time in Adelaide.

My deepest thanks go to Professor Hua-Dong Zhou, my supervisor at Daping Hospital in China, for paving the way for me to study in Australia, which guides me toward a bright future in my career.

I would like to acknowledge my family, especially my wife, Yan Lian, who undertook a great burden by allowing me to undertake this PhD. Despite her own
heavy and demanding responsibilities at work, she took care of my daughter and my parents while I was studying here. She has always stood by me, encouraged and supported me. Love to my beautiful daughter, Xuan-Yue Wang, while the separation was difficult for both of us, she was understanding of the circumstances and was a bright spot in my life during this time, providing me with never ending love and support.

My studies could not have been completed without the financial support provided from the International Postgraduate Research Scholarship from the Federal Government of Australia. I am also thankful for the opportunities to attend conferences provided by the Overseas Conference Travel Grant from the Department of Physiology, the Faculty of Health Sciences, and Flinders University.

To those who are not mentioned within this acknowledgement but have contributed and supported me throughout my studies, I thank you!

Yan-Jiang Wang

November 2009